Systemic delivery of biotherapeutics through the lung: Opportunities and challenges for improved lung absorption

Therapeutic Delivery

Volumn 4, Issue 12, 2013, Pages 1511-1525

  Sakagami, Masahiro ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; BLOOD CLOTTING FACTOR 9; CALCITONIN; CETRORELIX; CYCLOSPORIN; DESMOPRESSIN; DETIRELIX; ERYTHROPOIETIN; EXENDIN 4; FC SCFV FUSION PROTEIN; FOLLITROPIN; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 1; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HYBRID PROTEIN; IMMUNOGLOBULIN G; INSULIN; INSULIN ASPART; INSULIN LISPRO; LEUPRORELIN; LIPOSOME; MONOCLONAL ANTIBODY; PARATHYROID HORMONE[1-34]; PEPTIDE YY [3-36]; PEPTIDES AND PROTEINS; RECOMBINANT HUMAN INSULIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOSTATIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; ENZYMATIC DEGRADATION; LUNG; LUNG ALVEOLUS EPITHELIUM; LUNG DIFFUSION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TRANSCYTOSIS;

EID: 84890394930     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.119     Document Type: Review

References (93)

1. Zhong X, Neumann P, Corbo M, Loh E. Recent advances in biotherapeutics drug discovery and development. In: Drug Discovery and Development - Present and Future. Kapetonovic I (Ed.). InTech Europe, Rejeka, Croatia, 363-378 (2011
2. Schiffter HA. The delivery of drugs - peptides and proteins. In: Comprehensive Biotechnology (2nd Edition). Moo-Young M (Ed.). Pergamon Press (Elsevier), Oxford, UK, 587-604 (2011
3. Grant M, Leone-Bay A. Peptide therapeutics: It's all in the delivery. Ther. Deliv. 3(8), 981-996 (2012
4. Patton JS, Nagarajan S, Clark A. Pulmonary absorption and metabolism of peptides and proteins. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, Buffalo Grove, IL, USA, 17-24 (1998
5. Hastings RH, Folkesson HG, Matthay MA. Mechanisms of alveolar protein clearance in the intact lung. Am. J. Physiol. Lung Cell Mol. Physiol. 286(4), L679-L689 (2004
6. Patton JS, Fishburn CS, Weers JG. The lung as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1(4), 338-344 (2004
7. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules - principles, problems, and examples. J. Physiol. Pharmacol. 59(Suppl. 6), 53-79 (2008
8. Sakagami M, Nadkarni PN. Beyond insulin: The shrinking pulmonary delivery window for systemic biotech drugs. In: Respiratory Drug Delivery 2010. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (Eds). Davis Healthcare International Publishing, IL, USA, 31-38 (2010
9. Mcelroy MC, Kirton C, Gliddon D, Wolff RK. Inhaled biopharmaceutical drug development: Nonclinical considerations and case studies. Inhal. Toxicol. 25(4), 219-232 (2013
10. McMahon GT, Arky RA. Inhaled insulin for diabetes mellitus. N. Engl. J. Med. 356(5), 497-502 (2007
11. Siekmeier R, Scheuch G. Inhaled insulin - does it become reality? J. Physiol. Pharmacol. 59(Suppl. 6), 81-113 (2008
12. Heinemann L. The failure of Exubera: Are we beating a dead horse? J. Diabetes Sci. Technol. 2(3), 518-529 (2008
13. Shoyele SA, Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary delivery. Int. J. Pharm. 314(1), 1-8 (2006
14. Stegemann S, Kopp S, Borchard G et al. Developing and advancing dry powder inhalation towards enhanced therapeutics. Eur. J. Pharm. Sci. 48(1-2), 181-194 (2013
15. Exubera. Prescribing information. Pfizer Inc., NY, USA (2008
16. Bosquillon C. Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99(5), 2240-2255 (2010
17. Sakagami M, Gumbleton M. Targeted drug delivery through the respiratory system: Molecular control on lung absorption and disposition. In: Controlled Pulmonary Drug Delivery. Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 127-141 (2011
18. Taljanski W, Pierzynowski SG, Lundin PD et al. Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. Drug Metab. Dispos. 25(8), 917-920 (1997
19. Lizio R, Klenner T, Borchard G et al. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. Eur. J. Pharm. Sci. 9(3), 253-258 (2000
20. Niven RW, Whitcomb KL, Shaner L, Ip AY, Kinstler OB. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res. 12(9), 1343-1349 (1995
21. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins: A-interferon, calcitonin and parathyroid hormone. J. Control. Release 28(1-3), 79-85 (1994
22. Patton JS, McCabe JG, Hansen SE, Daugherty AL. Absorption of human growth hormone from the rat lung. Biotechnol. Ther. 1(3), 213-228 (1990
23. Gonda I. Drugs administered directly into the respiratory tract: Modeling of the duration of effective drug levels. J. Pharm. Sci. 77(4), 340-346 (1988
24. Lombry C, Edwards DA, Préat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am. J. Physiol. Lung Cell Mol. Physiol. 286(5), L1002-L1008 (2004
25. Sakagami M. Pulmonary insulin: A critical review of its biopharmaceutics. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood International Publishing, NC, USA, 48-57 (2002
26. Sakagami M. Insulin disposition in the lung following oral inhalation in humans: A meta-analysis of its pharmacokinetics. Clin. Pharmacokinet. 43(8), 539-552 (2004
27. Pang Y, Sakagami M. Importance of insulin association on pulmonary absorption and metabolism. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International Publishing, IL, USA, 48-57 (2004
28. Pang Y, Sakagami M, Byron PR. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition. Eur. J. Pharm. Sci. 25(4-5), 369-378 (2005
29. Pang Y, Sakagami M, Byron PR. Insulin self-association: Effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL). Pharm. Res. 24(9), 1636-1644 (2007
30. Taylor G, Colthorpe P, Farr SJ. Pulmonary absorption of proteins: Influence of deposition site and competitive elimination process. In: Respiratory Drug Delivery IV. Byron PR, Dalby RN, Farr SJ (Eds). Interpharm Press, Boca Raton, FL, USA, 25-30 (1994
31. Nadkarni P, Sakagami M. Diverse lung disposition kinetics for 4-6 kDa peptides following pulmonary delivery in rats: Implications to inhaled macromolecules for systemic delivery. AAPS J. 11(S2), 0902 (2011
32. Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabet. Care 28(5), 1077-1082 (2005
33. Farr SJ, McElduff A, Mather LE et al. Pulmonary insulin administration using the AERx® system: Physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. 2(2), 185-197 (2000
34. Yamahara H, Lehr CM, Lee VHL, Kim KJ. Fate of insulin during transit across rat alveolar epithelial cell monolayers. Eur. J. Pharm. Biopharm. 40(2), 294-298 (1994
35. Pohl R, Thrall RS, Rogers RA, Kramer PA. Confocal imaging of peripheral regions of intact rat lungs following intratracheal administration of 6-carboxyfluorescein, FITC-insulin, and FITC-dextran. Pharm. Res. 16(2), 327-332 (1999
36. Himmelmann A, Jendle J, Mellén A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 26(3), 677-682 (2003
37. DeFelippis MR, Chance RE, Frank BH. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit. Rev. Ther. Drug Carrier Syst. 18(2), 201-264 (2001
38. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: An example of applied science. Diabetes Obes. Metab. 11(1), 5-19 (2009
39. Liu F, Kildsig DO, Mitra AK. Insulin aggregation in aqueous media and its effect on a-chymotrypsin-mediated proteolytic degradation. Pharm. Res. 8(7), 925-929 (1991
40. Clark A, Kuo M-C, Newman S, Hirst P, Pitcairn G, Pickford M. A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. Pharm. Res. 25(7), 1583-1590 (2008
41. Nadkarni PP, Costanzo RM, Sakagami M. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Diabetes Obes. Metab. 13(5), 408-417 (2011
42. Nadkarni P, Sakagami M. Pulmonary delivery of oxyntomodulin and its fragments for appetite suppression in rats. AAPS J. 10(S2), M1178 (2008
43. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled technosphere insulin. Ann. Pharmacother. 44(7-8), 1231-1239 (2010
44. Rave K, Potocka E, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes. Metab. 11(7), 715-720 (2009
45. Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere® insulin: Defining the role of Technosphere particles at the cellular level. J. Diabetes Sci. Technol. 3(3), 545-554 (2009
46. Bitonti AJ, Dumont JA, Low SC et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl Acad. Sci. USA 101(26), 9763-9768 (2004
47. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 18(3), 294-303 (2005
48. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 58(9-10), 1106-1118 (2006
49. Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20(7), 1805-1813 (2005
50. Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: Impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20(3), 151-160 (2006
51. Kim K-J, Fandy TE, Lee VHL, Ann DK, Borok Z, Crandall ED. Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am. J. Physiol. Lung Cell Mol. Physiol. 287(3), L616-L622 (2004
52. Sakagami M, Omidi Y, Campbell L et al. Expression and transport functionality of FcRn within rat alveolar epithelium: A study in primary cell culture and in the isolated perfused lung. Pharm. Res. 23(2), 270-279 (2006
53. Sakagami M, Gumbleton M. Endogenous and exogenous IgG transfer in the airways: A prospective evaluation. In: Respiratory Drug Delivery 2006. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International Publishing, River Globe, IL, USA, 57-64 (2006
54. Sacaan AI, Edwards WR, Domingo D et al. Transport of aerosolized IL-2 chimeric protein using polymeric immunoglobulin receptor in the lung. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International Publishing, River Globe, IL, USA, 357-360 (2004
55. Rojas R, Apodaca G. Immunoglobulin transport across polarized epithelial cells. Nat. Rev. Mol. Cell Biol. 3(12), 944-955 (2002
56. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discov. 2(3), 214-221 (2003
57. Varonese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10(21), 1451-1458 (2005
58. Leach CL, Kuo M-C, Bueche B et al. Modifying the pulmonary absorption and retention of proteins through PEGylation. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Healthcare International Publishing, River Glove, IL, USA, 69-77 (2004
59. Lee KC, Chae SY, Kim TH, Lee S, Lee ES, Youn YS. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a Type 2 anti-diabetic agent. Regul. Pept. 152(1-3), 101-107 (2008
60. Youn YS, Kwon MJ, Na DH, Chae SY, Lee S, Lee KC. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. J. Control. Release 125(1), 68-75 (2008
61. Uchino T, Baudys M, Liu F, Song SC, Kim SW. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv. Drug Deliv. Rev. 35(2-3), 289-306 (1999
62. Hinds K, Koh JJ, Joss L, Liu F, Baudys M, Kim SW. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjugate Chem. 11(2), 195-201 (2000
63. Sakagami M, Byron PR. Respirable microspheres for inhalation: The potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin. Pharmacokinet. 44(3), 263-277 (2005
64. Shelth P, Myrdal PB. Polymers for pulmonary delivery. In: Controlled Pulmonary Drug Delivery. Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 265-282 (2011
65. Andrade F, Videira M, Ferreira D, Sarmento B. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine 6(1), 123-141 (2011
66. Swaminathan J, Ehrhardt C. Liposomes for pulmonary delivery. In: Controlled Pulmonary Drug Delivery. Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 313-334 (2011
67. Scott TL, Sullivan A, Proos R et al. Novel technology for fabrication of therapeutic microspheres for pulmonary delivery. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood International Publishing, Raleigh, NC, USA, 435-437 (2002
68. Morimoto K, Katsumata H, Yabuta T et al. Gelatin microspheres as a pulmonary delivery system: Evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol. 52(6), 611-617 (2000
69. Surendrakumar K, Martyn GP, Hodgers EC, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release 91(3), 385-394 (2003
70. Garcia-Contreras L, Morçöl T, Bell SJ, Hickey AJ. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci 5(2), E9 (2003
71. Tewes F, Gobbo OL, Amaro MI et al. Evaluation of HPbCD microparticles for salmon calcitonin administration via pulmonary delivery. Mol. Pharm. 8(5), 1887-1898 (2011
72. Hamishehkar H, Emami J, Najafabadi AR et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm. Drug Dispos. 31(2-3), 189-201 (2010
73. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release 62(1-2), 279-287 (1999
74. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm. 219(1-2), 75-80 (2001
75. Al-Qadi S, Grenha A, Carrion-Recio D, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations. J. Control. Release 157(3), 383-390 (2012
76. Blair J, Coghlan D, Langner E, Jansen M, Askey-Sarvar A. Sustained delivery of insulin via the lung using Solidose® technology. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood International Publishing, Raleigh, NC, USA, 411-413 (2002
77. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS PharmSciTech 6(3), E482-E486 (2005
78. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Control. Release 137(2), 104-109 (2009
79. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target. 16(9), 639-648 (2008
80. Zarogoulidis P, Chatzaki E, Porpodis K et al. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine. Int. J. Nanomedicine 7, 1551-1572 (2012
81. Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv. Drug Delv. Rev. 64(1), 1-15 (2012
82. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in Type 1 diabetes mellitus: The glucose stabilization effects of HIM2. Diabetes Tech. Ther. 4(4), 459-466 (2002
83. Druce MR, Minnion JS, Field BC et al. Investigation of structure-activity relationships of oxyntomodulin (OXM) using OXM analogs. Endocrinology 150(4), 1712-1722 (2009
84. Samad A, Sultana Y, Ail M. Liposomal drug delivery systems: An update review. Curr. Drug Deliv. 4(4), 297-305 (2007
85. Pasut G, Veronese FM. State of the art in PEGylation: The great versatility achieved after forty years of research. J. Control. Release 161(2), 461-472 (2012
86. Vick A, Wolff R, Koester A, Reams R, Deaver D, Heidel S. A 6-month inhalation study to characterize the toxicity, pharmacokinetics and pharmacodynamics of human insulin inhalation powder (HIIP) in beagle dogs. J. Aerosol Med. 20(2), 112-126 (2007
87. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. 90(6), 3287-3294 (2005
88. Alabraba V, Farnsworth A, Leigh R, Dodson P, Gough SC, Smyth T. Exubera inhaled insulin in patients with Type 1 and Type 2 diabetes: The first 12 months. Diabetes Technol. Ther. 11(7), 427-430 (2009
89. Heinemann L. New ways of insulin delivery. Int. J. Clin. Pract. 65, 31-46 (2011
90. Sicat BL, Morgan LA. New therapeutic options for the management of diabetes. Consult. Pharm. 22(1), 45-56 (2007
91. Pozilli P, Raskin P, Parkin CG. Review of clinical trials: Update on oral insulin spray formulation. Diabetes Obes. Metab. 12(2), 91-96 (2010
92. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 34(8), 1804-1808 (2011
93. Hoyer H, Perera G, Bernkop-Schnürch A. Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: A retroperspective. Drug Dev. Ind. Pharm. 36(1), 31-44 (2010